DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/9jp54q/key_findings_from) has announced the addition of Decision Resources, Inc's new report "Key Findings from Treatment Algorithms: Rheumatoid Arthritis - Disease-Modifying Agents" to their offering.
Physicians are increasingly initiating treatment with disease-modifying therapies for rheumatoid arthritis early in the course of the disease. Conventional, small molecule, disease-modifying antirheumatic agents (DMARDs) remain the mainstay of early-line treatment, but patients who fail such agents, patients with severe disease, or patients in whom conventional DMARDs are contraindicated are treated with biological DMARDs.
The most successful biological DMARDs in the RA market, TNF-a inhibitors, are threatened by several biological DMARDs with other mechanisms of action, which are experiencing strong uptake across multiple patient segments. Orencia (Bristol-Myers Squibb's abatacept), Rituxan (Biogen Idec/Roche's rituximab), and the recently launched Actemra (Roche's tocilizumab) are competing for share among patients who fail TNF-a inhibitors, and marketers of each of these agents aim to carve out additional niches of TNF-a inhibitor-naive RA patients for whom they could be prescribed.
Using patient-level claims data, this report determines the share of each currently marketed drug by line of therapy, evaluates therapy flow, and analyzes why key drugs are chosen over others.
Key Topics Covered:
2. Key Findings for Newly Diagnosed Patients
4. Key Findings by Product
5. Appendix: Methodology
For more information visit http://www.researchandmarkets.com/research/9jp54q/key_findings_from
Source: Decision Resources, Inc
Source: Research and Markets